The performance of SGM-101, a fluorochrome-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody intraoperative imaging agent for the delineation of primary and recurrent tumor and metastases in patients undergoing curative surgery for colorectal cancer will be compared to that of standard white light visualization in a multicenter, open-label, randomized, controlled, parallel arms clinical study.
The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard white light visualization during surgical resections of colorectal cancer.